Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission
Tumor Biology · 2024
DOI: 10.3233/tub-230016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tumor Biology, 2024. Verfasst von Thomas Muley und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational Lung Research Centre Heidelberg, Member of the German Centre for Lung Research, Heidelberg, Germany. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Despite successful response to first line therapy, patients with small-cell lung cancer (SCLC) often suffer from early relapses and disease progression. OBJECTIVE: To investigate the relevance of serum tumor markers for estimation of prognosis at several time points during the course of disease. METHODS: In a prospective, single-center study, serial assessments of progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), cytokeratin-19 fragments (CYFRA 21-1) and carcino-embryogenic antigen (CEA) were performed during and after chemotherapy in 232 SCLC patients, and correlated with therapy response and overall survival (OS). RESULTS: ProGRP, NSE and CYFRA 21-1 levels decreased quickly after the first chemotherapy cycle and correlated well with the radiological response. Either as single markers or in combination they provided valuable prognostic information regarding OS at all timepoints investigated: prior to first-line therapy, after two treatment cycles in patients with successful response to first-line therapy, and prior to the start of second-line therapy. Furthermore, they were useful for continuous monitoring during and after therapy and often indicated progressive disease several months ahead of radiological changes. CONCLUSIONS: The results indicate the great potential of ProGRP, NSE and CYFRA 21-1 for estimating prognosis and monitoring of SCLC patients throughout the course of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Lung Research Centre Heidelberg, Member of the German Centre for Lung Research, Heidelberg, Germany.
- Translational Research Unit, Thoraxklinik, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Pneumology and Respiratory Medicine, Thoraxklinik, University Hospital, Heidelberg, Germany.
- Diagnostic and Interventional Radiology, University Hospital, Heidelberg, Germany.
- Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
- Pathology Wiesbaden, Wiesbaden, Germany.
Zitieren
APA
Muley, T., Herth, F. J., Heussel, C. P., Kriegsmann, M., Thomas, M., Meister, M., Schneider, M. A., Wehnl, B., Mang, A., & Holdenrieder, S. (2024). Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. Tumor Biology. https://doi.org/10.3233/tub-230016
Vancouver
Muley T, Herth FJ, Heussel CP, Kriegsmann M, Thomas M, Meister M, et al. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. Tumor Biology. 2024. doi:10.3233/tub-230016
BibTeX
@article{Muley2024,
author = {Muley, Thomas and Herth, Felix J and Heussel, Claus Peter and Kriegsmann, Mark and Thomas, Michael and Meister, Michael and Schneider, Marc A and Wehnl, Birgit and Mang, Anika and Holdenrieder, Stefan},
title = {Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission},
journal = {Tumor Biology},
year = {2024},
doi = {10.3233/tub-230016}
}
EUVIMED